This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Intercept Pharmaceuticals (ICPT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intercept (ICPT) delivered earnings and revenue surprises of 17.74% and 0.76%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Intercept (ICPT) Gains on Solid Q2 Results, Ocaliva Recovers
by Zacks Equity Research
Intercept (ICPT) gains on a better-than-expected second quarter as loss narrows and sales surpass estimates on a significant recovery in Ocaliva.
Intercept (ICPT) Q2 Loss Narrower-Than-Expected
by Ekta Bagri
Intercept (ICPT) reports a narrower-than-expected loss in the second quarter of 2018. Revenues tops expectations.
What's in Store for Intercept (ICPT) This Earnings Season?
by Zacks Equity Research
Investors will primarily focus on Ocaliva's performance along with other pipeline developments, when Intercept (ICPT) reports its Q2 results on Aug 2.
Can AppFolio (APPF) Keep Earnings Streak Alive in Q2?
by Zacks Equity Research
AppFolio (APPF) second-quarter results are expected to benefit from increasing number of property manager customers and higher property manager units.
What's in the Store for IPG Photonics (IPGP) in Q2 Earnings?
by Zacks Equity Research
IPG Photonics (IPGP) is benefiting from strong adoption of fiber lasers over conventional lasers as well as non-laser cutting and welding equipment.
What's in the Offing for Castlight (CSLT) in Q2 Earnings?
by Zacks Equity Research
Castlight Health (CSLT) Q2 results to benefit from launch of Anthem Engage.
Celgene (CELG) Q2 Earnings: Disappointment in Store?
by Zacks Equity Research
Celgene Corporation (CELG) has been sailing in troubled waters, of late, and the recent pipeline setbacks might weigh on its performance in its second-quarter results.
Will HIV Sales Drive Gilead (GILD) to Beat in Q2 Earnings?
by Zacks Equity Research
Gilead (GILD) is likely to beat expectations in the second quarter propelled by the momentum in the HIV franchise.
4 Biotech Bets to Watch as Industry Rebounds in a Month
by Madhu Goel
The biotech sector makes a sharp rise in 30 days post the positive data read out from Biogen's mid-stage Alzheimer's trial on BAN2401. We recommend a few industry players for investors' portfolio boost.
5 Biotech Stocks Well Poised to Beat Q2 Earnings Estimates
by Zacks Equity Research
Biotech industry experiences a turnaround in June. Here are five stocks which are expected to beat expectation in Q2.
NASH Space in Focus as Galmed (GLMD) Posts Positive Data
by Ekta Bagri
Investor focus is back on the NASH space as quite a few companies release promising data on their NASH candidates of late.
Galmed (GLMD) Soars on Positive NASH Data on Aramchol
by Zacks Equity Research
Shares of Galmed Pharmaceuticals (GLMD) surges significantly following positive top-line results on lead candidate Aramchol in NASH patients.
Intercept (ICPT) Up 3.8% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Intercept (ICPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Madrigal's NASH Study Data Encouraging, Stock Skyrockets
by Zacks Equity Research
Madrigal Pharmaceuticals' (MDGL) thyroid hormone receptor, MGL-3196, achieves significantly sustained reduction in liver fat at week 36 in a phase II study evaluating it in NASH patients.
Intercept (ICPT) Q1 Loss Narrower Than Expected, Sales Lag
by Zacks Equity Research
Intercept's (ICPT) first-quarter results were mixed as loss was narrower than expectations but sales missed expectations. The company also provided Ocaliva sales guidance for 2018.
What's in Store for Intercept (ICPT) This Earnings Season?
by Zacks Equity Research
Investors are expected to focus on Ocaliva sales when Intercept (ICPT) reports first-quarter results (expected on May 3).
Intercept Reports Phase III Sub-Study Liver Biopsy Data
by Zacks Equity Research
Intercept (ICPT) announces data from the POISE biopsy sub-study which showed that treatment with obeticholic acid leads to the reversal or stabilization of fibrosis/cirrhosis in patients with primary biliary cholangitis.
Gilead (GILD) Presents Encouraging Data on NASH Therapies
by Zacks Equity Research
Gilead Sciences (GILD) announces encouraging data from a proof-of-concept study on experimental combination NASH therapies at The International Liver Congress 2018 in Paris.
Bristol-Myers Collaborates With Harvard Fibrosis Network
by Zacks Equity Research
Bristol-Myers (BMY) announces a research collaboration agreement with Harvard Fibrosis Network to discover and develop potential new therapies for fibrotic diseases, including fibrosis of the liver and heart.
Intercept Pharmaceuticals (ICPT) in Focus: Stock Moves 9.9% Higher
by Zacks Equity Research
Intercept Pharmaceuticals (ICPT) shares rose nearly 10% in the last trading session, amid huge volumes.
Intercept (ICPT) Up 6.7% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Intercept (ICPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Intercept (ICPT) Q4 Earnings & Sales Lag on Dull Ocaliva
by Zacks Equity Research
Intercept (ICPT) missed on both earnings and revenues in the fourth quarter as Ocaliva sales were drab due to safety issues of the drug.
Intercept (ICPT) Misses on Q4 Earnings & Sales
by Ekta Bagri
Intercept missed on earnings and sales estimates in the fourth quarter of 2017 due to weak Ocaliva sales.
Intercept Starts OCA Trial for NASH Patients With Cirrhosis
by Zacks Equity Research
Intercept (ICPT) initiates a randomized phase III trial, REVERSE, on obeticholic acid in subjects with compensated cirrhosis due to non-alcoholic steatohepatitis.